Letter to the editor on the paper: “The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing” by Sehr, Tony et al.
 
 
 
 
 
Dieses Dokument ist eine Zweitveröffentlichung (Verlagsversion) / 
This is a self-archiving document (published version):  
 
 
 
 
 
 
 
 
 
 
Diese Version ist verfügbar / This version is available on:  
https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-355284 
 
 
 
„Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFGgeförderten) Allianz- bzw. 
Nationallizenz frei zugänglich.“ 
 
This publication is openly accessible with the permission of the copyright owner. The permission is 
granted within a nationwide license, supported by the German Research Foundation (abbr. in German 
DFG). 
www.nationallizenzen.de/ 
 
 
 
Tony Sehr, Undine Proschmann, Katja Thomas, Tjalf Ziemssen 
Letter to the editor on the paper: “The majority of natalizumab-
treated MS patients have high natalizumab concentrations at time of 
re-dosing” 
 
Erstveröffentlichung in / First published in: 
Multiple Sclerosis Journal. 2018, 24(6), S. 820 – 822 [Zugriff am: 19.08.2019]. SAGE journals. 
ISSN 1477-0970. 
DOI: https://doi.org/10.1177/1352458517726384 
 
 
Multiple Sclerosis Journal 24(6)
820 journals.sagepub.com/home/msj
T cells, may be more important in cortical pathology 
than HLA class II molecules, which present antigens 
to CD4+ T cells.
We therefore propose to clarify three issues in future 
studies. First, as Yates et al.3 did not perform immu-
nostaining of CD4+ T cells, the presence or absence of 
CD4+ T cells around small cortical veins should be 
elucidated. Second, the exact location of fibrin(ogen) 
deposition in the MS cortex remains unclear. It is crit-
ical to clarify whether fibrin(ogen) is deposited 
around small cortical veins. Third, an association of 
any HLA class I gene allele with cortical lesions has 
never been reported, and therefore, we believe it is 
worth studying in the future.
In conclusion, our study2 and Yate’s study3 open a 
new pathway to study cortical lesion development, 
highlighting HLA and T cell-mediated mechanisms.
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Letter to the editor on the paper: “The 
majority of natalizumab-treated MS patients 
have high natalizumab concentrations at time 
of re-dosing”
Date received: 21 June 2017; revised: 18 July 2017; 
accepted: 23 July 2017
Van Kempen et al. described high natalizumab con-
centrations in their natalizumab-treated multiple scle-
rosis (MS) patients at time of re-dosing.1 Based on the 
literature research,2,3 the authors consider a natali-
zumab concentration above 2 µg/mL to be sufficient 
for an adequate alpha-4 integrin receptor saturation of 
above 70%.
Recently, we have demonstrated similar results using 
our new cell-based immunoassay to evaluate free 
natalizumab concentration, cell-bound natalizumab, 
and alpha-4 integrin receptor saturation as the key 
pharmacokinetic/pharmacodynamic parameters of 
natalizumab treatment in different in vivo settings.4 
We investigated the effects of treatment interval 
extension or treatment cessation.
In line with this study, for all patients treated on the pro-
posed 4-week treatment interval, we could demonstrate 
natalizumab concentrations above 2 µg/mL (mean, 
18.5 µg/mL; standard deviation (SD), ±15.3). This was 
associated with a cell-bound natalizumab relative inten-
sity of 3375 with SD of ±1545 by fluorescence-activated 
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cell sorting (FACS). We could demonstrate that a single 
natalizumab infusion leads to a 4.7-fold increase in free 
natalizumab concentration in serum while cell-bound 
natalizumab increases only 1.4-fold. For patients on 
longer treatment intervals, we could detect correspond-
ing lower free natalizumab concentrations (5 weeks: 
15.84 µg/mL, SD ±7.6; 8 weeks: 2.49 µg/mL, SD ±0.5). 
We found that distribution of the free serum antibody in 
vivo follows comparable rules as of regular immuno-
globulin G (IgG) which we could demonstrate by com-
bined cerebrospinal fluid (CSF)/serum analyses. In 
addition, our analysis could show that free and cell-
bound natalizumab were significantly correlated in 
serum (r = .49; p < .0014).
Several groups demonstrated an association between 
body weight and natalizumab binding, although these 
correlations are only weak.5,6 Muralidharan et al.7 
found that body weight predicts only a small amount 
of variability of natalizumab saturation indicating that 
other yet unknown factors must exist. We have addi-
tionally shown that natalizumab has a high binding 
affinity to alpha-4 integrin and that a significant cell–
cell exchange between saturated and unsaturated cells 
may exist. So, we expect that all cells with available 
very late antigen-4 (VLA-4) molecules on the surface 
as potential natalizumab binding sites will impact the 
amount of free and cell-bound natalizumab. For the 
peripheral and CSF compartments, we could already 
demonstrate this link between cell-bound natalizumab 
and ratio of free natalizumab concentration to cellular 
concentration.
Different methods to measure natalizumab saturation 
have been developed.7,8 We use the ratio of cell-bound 
natalizumab post-drug to pre-drug infusion. Thereby, 
we could show statistical significant differences in 
natalizumab cell-bound levels between different treat-
ment intervals (natalizumab saturation after 4 weeks 
is 64%, after 5 weeks is 55.2%, and after 8 weeks is 
34%), while higher interindividual differences occur 
with longer treatment intervals. Harrer et al.9 could 
demonstrate higher natalizumab saturation levels 
after a 8-week treatment holiday in 12 patients (CD8 
cells, 57%; interquartile range, 26%–64% and CD4 
cells, 67%; interquartile range, 38%–69%) with high 
interindividual variability.
The authors propose a prospective trial investigating 
longer natalizumab treatment intervals depending on 
assessment of free natalizumab concentrations. We do 
not consider the change of infusion interval length as 
helpful, and we would suggest an individual dose of 
natalizumab every 4 weeks to keep VLA-4 saturation 
constant. Further studies may identify optimal VLA-4 
saturation levels that lead to effective MS treatment 
without increasing risk of progressive multifocal leu-
koencephalopathy (PML). Until that, we should mon-
itor VLA-4 saturation to not over treat MS patients 
and keep PML risk low.
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Response to “Letter to the editor on the 
paper: The majority of natalizumab-
treated MS patients have high natalizumab 
concentrations at time of re-dosing”
Date received: 29 August 2017; accepted: 3 September 
2017
With great interest we have read the comment of Sehr 
et al.1 on our study: The majority of natalizumab-
treated MS patients have high natalizumab concentra-
tions at time of re-dosing.2
In our research, we find similar results as earlier pre-
sented by Sehr et al.,3 a mean natalizumab trough con-
centration in a 4-week infusion interval above 15 µg/
mL and a large variation inter-individually but stable 
concentrations intra-individually.2 The study of Sehr 
et al.3 complements our results with cell-bound natali-
zumab and alpha-4 integrin receptor saturation data.
As inter-individual free natalizumab concentrations 
can widely differ between patients, we fully agree with 
Sehr et al. that personalized-based natalizumab treat-
ments should be explored in clinical trials. When con-
sidering personalizing natalizumab treatment, there are 
two relevant options: to alter the dose to the individual 
patient or to alter the infusion interval. Although both 
options should be explored, we would like to underline 
the patients’ interest; a personalized infusion interval 
will decrease the frequent hospital visits and therefore 
may likely increase the patients’ quality of life. Also, 
fewer hospital visits will decrease hospital costs.
Natalizumab blocks alpha-4 integrin, and the concen-
tration of natalizumab just before the next infusion 
will be most critical with respect to blocking capacity. 
Both interval prolongation and dose reduction will 
result in reduced trough levels, and one option is not a 
priori preferred over the other with respect to satura-
tion of alpha-4 integrin.
If the natalizumab concentration is an important factor 
in relation to receptor blocking, there is room for 
individualized dosing regimens, given that standard 
dosing results in substantial variation in natalizumab 
trough levels. It is this variation that could be explored 
in order to arrive at dosing schemes tailored to the 
individual patient. We expect receptor saturation an 
important parameter in this respect, which we antici-
pate to be correlated with concentrations of serum 
natalizumab.
Sehr et al. opt for a personal dose–dependent treat-
ment and address an important point that alpha-4 inte-
grin receptor saturation should be constant and not 
drop with longer infusion intervals. Muralidharan 
et al.4 showed in extensive data on natalizumab phar-
macokinetics and pharmacodynamics that alpha-4 
integrin saturation overall stayed above 80% if free 
natalizumab concentration was above 10 µg/mL. 
When the infusion interval is concentration-guided 
and trough concentration is kept above 10 µg/mL, the 
saturation is expected to remain stable (above 80%). 
The extent to which a receptor saturation of >70%–
80% is required for optimal drug efficacy remains 
poorly investigated; the patients described by Sehr 
et al. receiving a 5-week infusion interval (N = 18) and 
a 8-week infusion interval (N = 18) were clinically 
stable with a mean trough receptor saturation of 
55.2% and 34%, respectively.
In conclusion, we would like to thank Sehr et al. for 
their interesting comment. We agree that personalized 
natalizumab treatment should be explored in clinical 
trials, either by a personalized dose or altered infusion 
interval, given that free natalizumab concentration 
remains above a certain threshold to maintain stable 
alpha-4 integrin receptor saturation.
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